聚乙二醇干扰素和利巴韦林治疗早期丙型肝炎病毒高变区 1（HVR-1）的变异性。

Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy.

机构信息

Department of Immunopathology of Infectious and Parasitic Diseases, Medical University of Warsaw, Poland.

出版信息

Adv Med Sci. 2012;57(2):370-4. doi: 10.2478/v10039-012-0024-8.

DOI:10.2478/v10039-012-0024-8

PMID:22968340

Abstract

PURPOSE

Genetic variability of hepatitis C virus (HCV) is considered to be an important factor defining viral pathogenesis, persistence and resistance to treatment. The aim of the present study was to characterize HCV genetic heterogeneity within a hypervariable region 1 (HVR-1) before and during the early period of pegylated interferon alfa (PEG-IFN-α) and ribavirin treatment in correlation with treatment outcome.

MATERIAL AND METHODS

The study involved 24 patients treated with PEG-IFN-α and ribavirin whose sera were collected before (baseline) and at 7, 14, 21 28 and 56 day of treatment. HCV HVR-1 region was amplified by nested RT- PCR and subjected to SSCP (single strand conformational polymorphism) analysis. SSCP changes of HCV HVR-1 over time in each patient were compared to treatment outcome results.

RESULTS

In 2/11 (18%) SVR+ and 8/13 (62%) SVR- treated patients, HVR-1 genetic changes manifested by new SSCP bands (new genetic variants) and were significantly more frequent in nonresponders (P <0.05).

CONCLUSIONS

Our results indicate that HCV HVR-1 variability during the early phase of PEG-IFN-α and ribavirin therapy may be predictive of treatment outcome.

摘要

目的

丙型肝炎病毒（HCV）的遗传变异性被认为是决定病毒发病机制、持续性和对治疗的耐药性的重要因素。本研究的目的是在聚乙二醇干扰素α（PEG-IFN-α）和利巴韦林治疗前和早期，描述 HCV 高变区 1（HVR-1）内的遗传异质性，并与治疗结果相关联。

材料和方法

本研究涉及 24 例接受 PEG-IFN-α和利巴韦林治疗的患者，在治疗前（基线）和治疗后第 7、14、21、28 和 56 天采集血清。通过嵌套 RT-PCR 扩增 HCV HVR-1 区，并进行 SSCP（单链构象多态性）分析。比较每个患者 HCV HVR-1 随时间的 SSCP 变化与治疗结果。